Erasca reported multiple confirmed and unconfirmed partial responses for its pan-RAS molecular glue ERAS-0015 during dose escalation. Notably, two confirmed partial responses and one unconfirmed partial response were observed at doses as low as 8 mg once daily, with an ongoing duration of response exceeding six months in several patients. The dose-limiting toxicity threshold has not yet been reached, and the safety profile remains favorable, with predominantly low-grade adverse events and well-behaved pharmacokinetics across all cohorts.

General counsel and corporate secretary Gar‍ner Ebun executed an option exercise and immediate share sale of 120,000 ERAS shares on January 7, generating gross proceeds of approximately $671,000. Post-transaction, direct holdings declined from 145,076 to 25,076 shares, representing an 82.7% reduction. Ebun retains 360,000 options outstanding, including both vested and unvested awards, preserving substantial capacity for future exercises under the existing Rule 10b5-1 plan established in June 2024.

As of the fourth quarter of 2025, Erasca reported total cash, cash equivalents and marketable securities of $362 million, sufficient to fund operations into the second half of 2028. Quarterly net losses narrowed modestly year over year, reflecting disciplined cost management. Research and development expenditures accounted for 75% of total operating expenses in 2025, underscoring the company's commitment to advancing its RAS-targeting franchise.

Erasca plans to present initial Phase 1 monotherapy data for ERAS-0015 in the first half of 2026, followed by the initiation of monotherapy expansion and combination cohorts in the second half. The company also anticipates collaborating with regulators to finalize a Phase 2 proof-of-concept study design, targeting enrollment of 60 patients with RAS-mutant solid tumors. These milestones will inform potential accelerated approval pathways and support broader combination strategies across the RAS/MAPK oncology landscape.